Biolife Solutions (BLFS) Liabilities and Shareholders Equity (2010 - 2026)

Biolife Solutions (BLFS) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $400.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 1.46% year-over-year to $400.9 million; the TTM figure through Mar 2026 stood at $1.6 billion (up 2.25% YoY), while the FY2025 annual figure was $405.9 million, up 1.6% from the prior year.
• Liabilities and Shareholders Equity retreated to $400.9 million in Q1 2026 per BLFS's latest filing, from $405.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $544.3 million in Q1 2022 and bottomed at $375.0 million in Q2 2024.
• Historically, Liabilities and Shareholders Equity has averaged $423.3 million across 5 years, with a median of $405.9 million in 2025.
• On a YoY basis, Liabilities and Shareholders Equity climbed as much as 126.76% in 2022 and fell as far as 18.77% in 2022.
• Biolife Solutions' Liabilities and Shareholders Equity stood at $450.2 million in 2022, then retreated by 8.33% to $412.7 million in 2023, then slipped by 3.2% to $399.5 million in 2024, then gained by 1.6% to $405.9 million in 2025, then fell by 1.23% to $400.9 million in 2026.
• Business Quant data shows BLFS's Liabilities and Shareholders Equity at $400.9 million in Q1 2026, $405.9 million in Q4 2025, and $392.1 million in Q3 2025.